This JAMA piece is truly interesting. Was quite intrigued by the zero intracranial bleeds with apixaban vs 7 with aspirin. (The authors do concede that this may be a chance outcome.)
They also mention that the all-cause mortality data presented a noticeably different picture for the two groups, with 12 deaths in the Apixaban group and 8 a…
This JAMA piece is truly interesting. Was quite intrigued by the zero intracranial bleeds with apixaban vs 7 with aspirin. (The authors do concede that this may be a chance outcome.)
They also mention that the all-cause mortality data presented a noticeably different picture for the two groups, with 12 deaths in the Apixaban group and 8 among patients receiving aspirin.
"The secondary safety outcome of all-cause mortality occurred in 12 patients receiving apixaban (annualized rate, 1.8%) and 8 patients receiving aspirin (annualized rate, 1.2%) (HR, 1.53 [95% CI, 0.63-3.75])."
Would have appreciated a deeper look at both of these safety outcomes.
This JAMA piece is truly interesting. Was quite intrigued by the zero intracranial bleeds with apixaban vs 7 with aspirin. (The authors do concede that this may be a chance outcome.)
They also mention that the all-cause mortality data presented a noticeably different picture for the two groups, with 12 deaths in the Apixaban group and 8 among patients receiving aspirin.
"The secondary safety outcome of all-cause mortality occurred in 12 patients receiving apixaban (annualized rate, 1.8%) and 8 patients receiving aspirin (annualized rate, 1.2%) (HR, 1.53 [95% CI, 0.63-3.75])."
Would have appreciated a deeper look at both of these safety outcomes.